|
Total Return Securities Fund
|
||||||||
|
Schedule of Investments
|
||||||||
|
March 31, 2025 (Unaudited)
|
||||||||
|
COMMON STOCKS - 22.0%
|
Shares
|
Value
|
||||||
|
Food - 15.0%
|
||||||||
|
Aryzta AG (a)
|
1,189,000
|
$
|
2,635,354
|
|||||
|
Nestle SA
|
163,900
|
16,550,241
|
||||||
|
19,185,595
|
||||||||
|
Healthcare- Products - 1.2%
|
||||||||
|
Spineart SA (a)(b)
|
221,085
|
1,511,799
|
||||||
|
Retail - 5.8%
|
||||||||
|
Cie Financiere Richemont SA
|
43,400
|
7,502,718
|
||||||
|
TOTAL COMMON STOCKS (Cost $15,522,711)
|
28,200,112
|
|||||||
|
MASTER LIMITED PARTNERSHIPS - 0.3%
|
Units
|
Value
|
||||||
|
Biotechnology - 0.3%
|
||||||||
|
Aravis Biotech II, Limited Partnership (a)(b)(c)
|
3,294,705
|
440,833
|
||||||
|
TOTAL MASTER LIMITED PARTNERSHIPS (Cost
$213,885)
|
440,833
|
|||||||
|
CLOSED-END FUNDS - 0.0%(d)
|
Shares
|
Value
|
||||||
|
Central Securities Corp.
|
200
|
8,992
|
||||||
|
TOTAL CLOSED-END FUNDS (Cost $8,974)
|
8,992
|
|||||||
|
TOTAL INVESTMENTS - 22.3% (Cost $15,745,570)
|
28,649,937
|
|||||||
|
Money Market Deposit Account - 76.3% (e)
|
97,601,401
|
|||||||
|
Other Assets in Excess of Liabilities - 1.4%
|
1,749,218
|
|||||||
|
TOTAL NET ASSETS - 100.0%
|
$
|
128,000,556
|
||||||
|
|
||||||||
|
Percentages are stated as a percent of net assets.
|
||||||||
|
THE SWISS HELVETIA FUND, INC.
|
||||||||||||||||||||||||||||||||
|
|
March 31, 2025
|
|||||||||||||||||||||||||||||||
|
(continued)
|
||||||||||||||||||||||||||||||||
|
(a) Non-income producing security.
|
||||||||||||||||||||||||||||||||
|
(b) Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Adviser, acting as Valuation
Designee. These securities represented $1,952,632 or 1.5% of net assets as of March 31, 2025.
|
||||||||||||||||||||||||||||||||
|
(c) Affiliated security as defined by the Investment Company Act of 1940.
|
||||||||||||||||||||||||||||||||
|
Value
|
Gross
|
Gross
|
Corporate
|
Realized
|
Unrealized
|
Interest
|
Value
|
|||||||||||||||||||||||||
|
Name of Issuer
|
as of 12/31/24
|
Additions
|
Reductions
|
Actions
|
Gain/(Loss)
|
Gain/(Loss)
|
Income
|
as of 3/31/25
|
||||||||||||||||||||||||
|
Aravis Biotech II, Limited Partnership
|
$
|
427,248
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
13,585
|
$
|
-
|
$
|
440,833
|
||||||||||||||||
|
$
|
427,248
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
13,585
|
$
|
-
|
$
|
440,833
|
|||||||||||||||||
|
(d) Represents less than 0.05% of net assets.
|
||||||||||||||||||||||||||||||||
|
(e)The U.S. Bank Money Market Deposit Account (the “MMDA”) is a short-term vehicle in which the Fund holds cash balances. The MMDA will bear interest at a variable rate
that is determined based on market conditions and is subject to change daily. The rate as of March 31, 2025 was 3.31%.
|
||||||||||||||||||||||||||||||||
|
See Notes to Schedule of Investments
|
||||||||||||||||||||||||||||||||
|
PORTFOLIO HOLDINGS
|
||||
|
% of Net Assets as of March 31, 2025
|
||||
|
Food
|
15.0
|
%
|
||
|
Healthcare-Products
|
1.2
|
%
|
||
|
Retail
|
5.8
|
%
|
||
|
Biotechnology
|
0.3
|
%
|
||
|
Closed-End Funds
|
0.0
|
%
|
||
|
Money Market Deposit Account
|
76.3
|
%
|
||
|
Other Assets Less Liabilities
|
1.4
|
%
|
||
|
100
|
%
|
|||
|
TOP 10 PORTFOLIO HOLDINGS
|
||||
|
% of Net Assets as of March 31, 2025
|
||||
|
Nestle SA
|
12.93
|
%
|
||
|
Cie Financiere Richemont SA
|
5.86
|
%
|
||
|
Aryzta AG
|
2.06
|
%
|
||
|
SPINEART SA
|
1.18
|
%
|
||
|
ARAVIS BIOTECH II LP
|
0.34
|
%
|
||
|
Central Securities Corp
|
0.01
|
%
|
||
|
TOPIC 820 TABLE
|
||||||||||||||||||||
|
Investments in Securities*
|
Level 1
Quoted Prices |
Level 2
Other Significant Observable Inputs |
Level 3
Significant Unobservable Inputs |
Investments Valued
at NAV**
|
Total
|
|||||||||||||||
|
Common Stock
|
$
|
26,688,313
|
$
|
-
|
$
|
1,511,799
|
$
|
-
|
$
|
28,200,112
|
||||||||||
|
Master Limited Partnerships
|
-
|
-
|
-
|
440,833
|
440,833
|
|||||||||||||||
|
Closed-End Funds
|
8,992
|
-
|
-
|
-
|
8,992
|
|||||||||||||||
|
Total Investments in Securities
|
$
|
26,697,305
|
$
|
-
|
$
|
1,511,799
|
$
|
440,833
|
$
|
28,649,937
|
||||||||||
|
LEVEL 3 ROLLFORWARD TABLE
|
||||||||
|
Common Stock
|
Total
|
|||||||
|
Balance as of December 31, 2024
|
$
|
1,400,307
|
$
|
1,400,307
|
||||
|
Change in Unrealized Appreciation/Depreciation
|
111,492
|
111,492
|
||||||
|
Net Realized Gain (Loss)
|
-
|
-
|
||||||
|
Gross Purchases
|
-
|
-
|
||||||
|
Gross Sales
|
-
|
-
|
||||||
|
Transfer out of Level 3
|
-
|
-
|
||||||
|
Balance as of March 31, 2025
|
$
|
1,511,799
|
$
|
1,511,799
|
||||
|
Change in unrealized appreciation (depreciation) during the period for Level 3 investments held at March 31, 2025
|
111,492
|
111,492
|
||||||
|
(a)
|
The noted amounts of change in unrealized appreciation/depreciation relate to the fair value of Level 3 assets held on March 31, 2025.
|